Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

• المؤلفون الرئيسيون: Moreau, P, Joshua, D, Chng, W-J, Palumbo, A, Goldschmidt, H, Hajek, R, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosinol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Aggarwal, S, Feng, S, Dimopoulos, MA
• مؤلفون آخرون: DEAN'S OFFICE (MEDICINE)
• التنسيق: مقال
• اللغة: English
• منشور في: NATURE PUBLISHING GROUP 2022
• الموضوعات: Science & Technology; Life Sciences & Biomedicine; Oncology; Hematology; STEM-CELL TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; RETREATMENT; INHIBITOR
• الوصول للمادة أونلاين: https://scholarbank.nus.edu.sg/handle/10635/229017
• المؤسسة: National University of Singapore

10.1038/leu.2016.186